Addex Therapeutics Ltd Stock Prediction and Forecast [ADXN]
1 extracted signal · 1 resolved · 0 still active
StockInvest.usIndependent analyst profile- Source published
- 12 Sept 2025, 04:04 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC
![Video preview for Addex Therapeutics Ltd Stock Prediction and Forecast [ADXN]](https://i.ytimg.com/vi/BAtuhCk_0eY/hqdefault.jpg)
AI-generated source summary
This analysis focuses on Addex Therapeutics (ADXN). On September 11, 2025, the system ranked ADXN as a buy candidate with a score of 2.26. Since September 9th, there's been a 4.65% gain, averaging 1.55% daily. The analysis notes ADXN broke through a declining short-term trend, suggesting a potential trend shift. Support is expected at $8.75, potentially leading to an upward movement. According to fan theory, the next peak could be $10.55, a resistance level. The three-month trend anticipates a 9.9% decline, with a possible return range of -28.67% to -10.20%. The 12-month analysis projects a -12.63% change, placing the future price between $5.15 and $8.61. On September 11, 2025, the stock increased by 5.15%, closing at $8.78, following significant price fluctuation of 12.56% between high and low ($7.80 and $8.78). Over the prior 2 weeks, there's an 11.14% gain. There are positive indicators including a Moving Average Convergence Divergence buy signal, a buy signal generated 14 days ago from a pivot bottom, as trading volume increased. Weekly volatility is high, though, at 7.10% and it is a medium risk stock. Fibonacci analysis shows the 1st resistance for the stock is $9.43 .The price to earnings ratio is 0.656. The stop-loss should be at $8.47, according to this analysis.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
StockInvest.us
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.
